業績集【Selected papers】

• Response to Imatinib in a Patient With Gastric Adenocarcinoma With KIT Q556_K558 In-Frame Deletion: A Case Report.
  Ninomiya K, Ennishi D, Okamoto K, Ando M, Nakamura S, Tomida S, Ayada Y, Makimoto G, Ichihara E, Okita N, Toyooka S, Maeda Y, Tabata M.
  JCO Precis Oncol. 2024 doi: 10.1200/PO.24.00228.
• Topical application of activator protein-1 inhibitor T-5224 suppresses inflammation and improves skin barrier function in a murine atopic dermatitis-like dermatitis.
  Sasakura M, Urakami H, Tachibana K, Ikeda K, Hasui KI, Matsuda Y, Sunagawa K, Ennishi D, Tomida S, Morizane S.
  Allergol Int. 2024 doi: 10.1016/j.alit.2023.12.006.
• Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study.
  Dupuis J, Bachy E, Morschhauser F, Cartron G, Fukuhara N, Daguindau N, Casasnovas RO, Snauwaert S, Gressin R, Fox CP, d'Amore FA, Staber PB, Tournilhac O, Bouabdallah K, Thieblemont C, André M, Rai S, Ennishi D, Gkasiamis A, Nishio M, Fornecker LM, Delfau-Larue MH, Sako N, Mule S, de Leval L, Gaulard P, Tsukasaki K, Lemonnier F.
  Lancet Haematol.
  2024 doi: 10.1016/S2352-3026(24)00102-9.
• Understanding the intrinsic biology of diffuse large B-cell lymphoma: recent advances and future prospects.
  Naoi Y, Ennishi D.
  Int J Hematol. 2024 doi: 10.1007/s12185-024-03780-6.
• Topical application of activator protein-1 inhibitor T-5224 suppresses inflammation and improves skin barrier function in a murine atopic dermatitis-like dermatitis.
  Sasakura M, Urakami H, Tachibana K, Ikeda K, Hasui KI, Matsuda Y, Sunagawa K, Ennishi D, Tomida S, Morizane S.
  Allergol Int. 2024 Apr;73(2):323-331. doi: 10.1016/j.alit.2023.12.006.
• A Learning Program for Treatment Recommendations by Molecular Tumor Boards and Artificial Intelligence.
  Sunami K, Naito Y, Saigusa Y, Amano T, Ennishi D, Imai M, Kage H, Kanai M, Kenmotsu H, Komine K, Koyama T, Maeda T, Morita S, Sakai D, Hirata M, Ito M, Kozuki T, Sakashita H, Horinouchi H, Okuma Y, Takashima A, Kubo T, Hironaka S, Segawa Y, Yakushijin Y, Bando H, Makiyama A, Suzuki T, Kinoshita I, Kohsaka S, Ohe Y, Ishioka C, Yamamoto K, Tsuchihara K, Yoshino T.
  JAMA Oncol. 2024 doi: 10.1001/jamaoncol.2023.5120.
• Periostin secreted by cancer-associated fibroblasts promotes cancer progression and drug resistance in non-small cell lung cancer.
  Takatsu F, Suzawa K, Tomida S, Thu YM, Sakaguchi M, Toji T, Ohki M, Tsudaka S, Date K, Matsuda N, Iwata K, Zhu Y, Nakata K, Shien K, Yamamoto H, Nakayama A, Okazaki M, Sugimoto S, Toyooka S.
  J Mol Med (Berl). 2023 doi: 10.1007/s00109-023-02384-7.
• Distribution and clinical impact of molecular subtypes with dark zone signature of DLBCL in a Japanese real-world study.
  Urata T, Naoi Y, Jiang A, Boyle M, Sunami K, Imai T, Nawa Y, Hiramatsu Y, Yamamoto K, Fujii S, Yoshida I, Yano T, Chijimatsu R, Murakami H, Ikeuchi K, Kobayashi H, Tani K, Ujiie H, Inoue H, Tomida S, Yamamoto A, Kondo T, Fujiwara H, Asada N, Nishimori H, Fujii K, Fujii N, Matsuoka KI, Sawada K, Momose S, Tamaru JI, Nishikori A, Sato Y, Yoshino T, Maeda Y, Scott DW, Ennishi D.
  Blood Adv. 2023 doi: 10.1182/bloodadvances.2023010402.
• Utility of Comprehensive Genomic Profiling for Precise Diagnosis of Pediatric-Type Diffuse High-Grade Glioma.
  Makino K, Otani Y, Fujii K, Ishida J, Hirano S, Suruga Y, Washio K, Nishida K, Yanai H, Tomida S, Ennishi D, Date I.
  Acta Med Okayama. 2023 doi: 10.18926/AMO/65502.
• Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial. Shimada K, Yamaguchi M, Atsuta Y, Matsue K, Sato K, Kusumoto S, Nagai H, Takizawa J, Fukuhara N, Nagafuji K, Miyazaki K, Ohtsuka E, Okamoto M, Sugita Y, Uchida T, Kayukawa S, Wake A, Ennishi D, Kondo Y, Izumi T, Kin Y, Tsukasaki K, Hashimoto D, Yuge M, Yanagisawa A, Kuwatsuka Y, Shimada S, Masaki Y, Niitsu N, Kiyoi H, Suzuki R, Tokunaga T, Nakamura S, Kinoshita T.
  Lancet Oncol. 2020 doi: 10.1016/S1470-2045(20)30059-0.
• TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma.
  Ennishi D, Healy S, Bashashati A, Saberi S, Hother C, Mottok A, Chan FC, Chong L, Abraham L, Kridel R, Boyle M, Meissner B, Aoki T, Takata K, Woolcock BW, Viganò E, Gold M, Molday LL, Molday RS, Telenius A, Li MY, Wretham N, Dos Santos N, Wong M, Viller NN, Uger RA, Duns G, Baticados A, Madero A, Bristow BN, Farinha P, Slack GW, Ben-Neriah S, Lai D, Zhang AW, Salehi S, Shulha HP, Chiu DS, Mostafavi S, Gerrie AS, Huang DW, Rushton C, Villa D, Sehn LH, Savage KJ, Mungall AJ, Weng AP, Bally MB, Morin RD, Cohen Freue GV, Staudt LM, Connors JM, Marra MA, Shah SP, Gascoyne RD, Scott DW, Steidl C.
  Nat Med. 2020 doi: 10.1038/s41591-020-0757-z.
• Toward a New Molecular Taxonomy of Diffuse Large B-cell Lymphoma.
  Ennishi D, Hsi ED, Steidl C, Scott DW.
  Cancer Discovery. 2020 Sep;10(9):1267-1281.
• Impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of falsenegative MYC IHC.
  Collinge BJ, Ben-Neriah S, Chong LC, Boyle M, Jiang A, Miyata-Takata T, Farinha P, Craig JW, Slack GW, Ennishi D, Mottok A, Meissner B, Chavez EA, Gerrie AS, Villa D, Freeman CL, Savage KJ, Sehn LH, Morin RD, Mungall AJ, Gascoyne RD, Marra MA, Connors JM, Steidl C, Scott DW.
  Blood. 2020 doi: 10.1182/blood.2020007193.
• The heterodimer S100A8/A9 is a potent therapeutic target for idiopathic pulmonary fibrosis.
  Araki K, Kinoshita R, Tomonobu N, Gohara Y, Tomida S, Takahashi Y, Senoo S, Taniguchi A, Itano J, Yamamoto KI, Murata H, Suzawa K, Shien K, Yamamoto H, Okazaki M, Sugimoto S, Ichimura K, Nishibori M, Miyahara N, Toyooka S, Sakaguchi M.
  J Mol Med (Berl). 2020 doi: 10.1007/s00109-020-02001-x.
• Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical Trial.
  Hayashi H, Takiguchi Y, Minami H, Akiyoshi K, Segawa Y, Ueda H, Iwamoto Y, Kondoh C, Matsumoto K, Takahashi S, Yasui H, Sawa T, Onozawa Y, Chiba Y, Togashi Y, Fujita Y, Sakai K, Tomida S, Nishio K, Nakagawa K.
  JAMA Oncol. 2020 doi: 10.1001/jamaoncol.2020.4643.
• Diameter Is a Key 3D Characteristic for Assessments of Efficient Inhibitors of Protein-Protein Interactions.
  Nakadai M, Tomida S.
  J Chem Inf Model. 2020 doi: 10.1021/acs.jcim.0c00607.
• Overcoming epithelial-mesenchymal transition-mediated drug resistance with monensin-based combined therapy in non-small cell lung cancer.
  Ochi K, Suzawa K, Tomida S, Shien K, Takano J, Miyauchi S, Takeda T, Miura A, Araki K, Nakata K, Yamamoto H, Okazaki M, Sugimoto S, Shien T, Yamane M, Azuma K, Okamoto Y, Toyooka S.
  Biochem Biophys Res Commun. 2020 doi: 10.1016/j.bbrc.2020.06.077.